In the 20 years since its introduction to the palette of intravenous hemodynamic therapies, the inodilator levosimendan has established itself as a valuable asset for the management of acute decompensated heart failure. Its pharmacology is notable for delivering inotropy via calcium sensitization without an increase in myocardial oxygen consumption.
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety / Heringlake, Matthias; Alvarez, Julian; Bettex, Dominique; Bouchez, Stefaan; Fruhwald, Sonja; Girardis, Massimo; Grossini, Elena; Guarracino, Fabio; Herpain, Antoine; Toller, Wolfgang; Tritapepe, Luigi; Pollesello, Piero. - In: EXPERT REVIEW OF CARDIOVASCULAR THERAPY. - ISSN 1477-9072. - (2021). [10.1080/14779072.2021.1905520]
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety
Tritapepe, LuigiValidation
;
2021
Abstract
In the 20 years since its introduction to the palette of intravenous hemodynamic therapies, the inodilator levosimendan has established itself as a valuable asset for the management of acute decompensated heart failure. Its pharmacology is notable for delivering inotropy via calcium sensitization without an increase in myocardial oxygen consumption.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
